Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Breast cancer, early stage

1423 - High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with _4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study

Date

19 Oct 2018

Session

Proffered paper session - Breast cancer, early stage

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Tessa Steenbruggen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

T.G. Steenbruggen1, L.C. Steggink2, C.M. Seynaeve3, J.J.M. van der Hoeven4, M.J. Hooning5, A. Jager3, I.R. Konings6, J.R. Kroep7, W.M. Smit8, V.C.G. Tjan-Heijnen9, E. van der Wall10, A.D. Bins11, S.C. Linn1, M. Schaapveld12, F.E. van Leeuwen12, C.P. Schroder2, H. van Tinteren13, E.G..E. de Vries14, G.S. Sonke1, J.A. Gietema14

Author affiliations

  • 1 Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2 Medical Oncology, University Medical Center Groningen, Groningen/NL
  • 3 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA - Rotterdam/NL
  • 4 Medical Oncology, Radboud University, Nijmegen/NL
  • 5 Department Of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam/NL
  • 6 Medical Oncology, Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL
  • 7 Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 8 Medical Oncology, Medisch Spectrum Twente (MST), 7500 KA - Enschede/NL
  • 9 Medical Oncology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 10 Cancer Center, UMC - University Medical Center Utrecht, 3584 CX - Utrecht/NL
  • 11 Medical Oncology F4-224, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 12 Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 13 Biostatistics, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 14 Medical Oncology, University Medical Center Groningen, 9700 RB - Groningen/NL
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1423

Background

Adjuvant HDCT for high-risk BC is not beneficial overall compared to conventional chemotherapy at the cost of considerable toxicity. HDCT benefit, however, may be present in very high-risk patients (i.e. >9 involved ALN) and in triple negative (TN) BC patients, although long-term results are lacking for most initial studies. We evaluated long-term outcome of a randomized phase 3 study, conducted from 1993 to 99.

Methods

Patients aged <56 years with early BC and ≥4 involved ALN were randomized to either conventional chemotherapy or HDCT as adjuvant systemic treatment. The conventional arm consisted of 5x fluorouracil, epirubicin and cyclophosphamide (FEC) 3-weekly. In the HDCT arm, the 5th FEC was replaced by cyclophosphamide 6000 mg/m2, thiotepa 480 mg/m2, carboplatin 1600 mg/m2 and supported with autologous HSCT (Rodenhuis, NEJM 2003). We collected 20-year follow-up data from medical records, general practitioners, and the Netherlands Cancer Registry. Endpoints were relapse free survival (RFS), overall survival (OS), BC specific survival (BCSS), and safety based on intention to treat analyses.

Results

885 patients (64% 4-9 ALN, 36% >9 ALN; 53% ER+/HER2-, 23% HER2+, 16% TN, 8% unknown) were randomized to FEC (n = 443) or HDCT (n = 442). The table shows efficacy results of univariable Cox models. With 20 years median follow-up, relapse or death occurred in 272 patients (61%) who received FEC vs in 257 (58%) HDCT patients (HR 0.88; 95% CI 0.74-1.05). The effect of HDCT compared to FEC was most pronounced in patients with >9 involved ALN and in TNBC patients. In 138 TNBC patients the 20-year OS estimate was 52% after HDCT vs 39% after FEC. Long-term safety and BCSS will also be presented at the meeting.Table: 187O

RFSHDCTFEC
N20 yr (%)95% CI20 yr (%)95% CIHR95% CIp
All8854237-473833-430.880.74-1.050.15
4-9 ALN5684338-504438-501.000.81-1.250.97
>9 ALN3173931-472721-360.710.54-0.940.02
ER+/HER2-4694034-473630-430.830.66-1.040.11
HER2+2053830-494233-521.150.80-1.630.46
TN1385140-653424-480.660.42-1.030.07
OSHDCTFEC
N20 yr (%)95% CI20 yr (%)95% CIHR95% CIp
All8854541-504137-460.890.74-1.060.18
4-9 ALN5684640-524842-541.010.81-1.270.91
>9 ALN3174437-533023-380.720.54-0.950.02
ER+/HER2-4694640-534034-470.810.64-1.030.09
HER2+2054032-514637-561.150.80-1.660.44
TN1385241-653929-520.710.45-1.120.14

Conclusions

Long-term follow-up confirms survival benefit of HDCT in BC patients with >9 involved ALN and suggests benefit in TNBC patients.

Clinical trial identification

NCT03087409.

Legal entity responsible for the study

High-risk breast cancer study group from the Netherlands Working Party on Autologous Transplantation in Solid Tumors.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

T.G. Steenbruggen: Financial support: Memidis Pharma unrelated to the submitted work. V.C.G. Tjan-Heijnen: Research funding through grants institution: Eisai, Roche, Pfizer, Novartis, and AstraZeneca; Compensation for service as a consultant: AstraZeneca, Pfizer, Novartis, and Roche; Honoraria: Pfizer, Roche, and Novartis; Travel expenses: Pfizer, Novartis, and Roche. S.C. Linn: Institutional research funding: AstraZeneca, Amgen, BMS, Genentech, Roche, and Sanofi; Advisory board member: AstraZeneca, Novartis, Roche and Sanofi. E.G.E. de Vries: Consulting/advisory board fees: Synthon, Pfizer and Sanofi; Grants: Novartis, Amgen, Roche/Genentech, Regeneron, Chugai, Synthon, AstraZeneca, Radius Health, CytomX Therapeutics and Nordic Nanovector, all to the hospital and unrelated to the submitted work. G.S. Sonke: Institutional research funding: AstraZeneca, Merck, Novartis, Roche, unrelated to the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.